LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded LeMaitre Vascular (NASDAQ:LMAT) from a "hold" to a "buy" rating, contributing to a consensus "Moderate Buy" rating among analysts with an average target price of $100.20. The medical instruments supplier currently trades at $92.94, with a market capitalization of $2.11 billion. Institutional investors hold a significant portion of the stock, with major firms like Vanguard and First Trust increasing their positions.
LeMaitre Vascular (LMAT) Expected to Announce Earnings on Wednesday
LeMaitre Vascular (NASDAQ:LMAT) is scheduled to announce its Q4 2025 earnings after the market closes on Wednesday, February 25th. Analysts project earnings per share of $0.67 and revenue of $62.98 million. The stock currently trades around $89.25 with a market cap of $2.03 billion, and analysts have a "Moderate Buy" consensus rating with a target price of $100.20.
Behavioral Patterns of LMAT and Institutional Flows
This article analyzes Lemaitre Vascular Inc. (NASDAQ: LMAT) using AI models, determining a neutral sentiment across all time horizons. It highlights an exceptional 29.8:1 risk-reward setup targeting an 8.6% gain, and outlines specific position, momentum, and risk-hedging trading strategies. The analysis provides support and resistance levels for near-term, mid-term, and long-term trading.
A Look At LeMaitre Vascular (LMAT) Valuation After Recent Share Price Move And Mixed Return Profile
LeMaitre Vascular (LMAT) has seen recent share price movements, with a 9.34% year-to-date increase but a 10.32% decline over one year, despite strong long-term returns. The article explores the company's valuation, noting it appears 16.3% undervalued based on revenue and net income growth driven by an expanding patient population, potentially reaching a fair value of $104.78. However, its high P/E ratio of 37.3x, significantly above industry and peer averages, suggests market optimism that may not be fully justified.
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. A conference call is scheduled for 5:00 PM EST on the same day to discuss the results, business highlights, and company outlook. The company specializes in devices, implants, and services for peripheral vascular disease.
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. A conference call is scheduled for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Registration is required for access to the live call, and an audio webcast will also be available.
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Expensive For A Reason? A Look At Its Intrinsic Value
This article examines the intrinsic value of LeMaitre Vascular, Inc. (LMAT) using a two-stage Discounted Cash Flow (DCF) model. The analysis suggests that LeMaitre Vascular is currently overvalued by 27% with a fair value estimate of US$68.78, compared to its current share price of US$87.42. The article also notes that analyst price targets are significantly higher, indicating differing valuation perspectives.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of "Moderate Buy" by Brokerages
Eight brokerage firms have given LeMaitre Vascular, Inc. (NASDAQ:LMAT) a "Moderate Buy" consensus rating, with an average 1-year price target of $100.20. The company reported Q1 EPS of $0.62, beating estimates, though revenue of $61.05 million slightly missed expectations. LeMaitre Vascular has a market capitalization of $1.98 billion, with institutional investors holding approximately 84.64% of its shares.
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
LeMaitre Vascular (NASDAQ:LMAT) has attracted investor attention due to its impressive earnings per share growth of 35% annually over the last three years and expanding EBIT margins. Insiders hold a significant US$159 million stake in the company, aligning their interests with shareholders, and the CEO's compensation is modest compared to peers. These factors suggest LeMaitre Vascular is a company worth monitoring.
Ranger Investment Management L.P. Lowers Stock Position in LeMaitre Vascular, Inc. $LMAT
Ranger Investment Management L.P. significantly reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 25% in the third quarter of 2025, selling 128,274 shares and retaining 385,800 shares valued at approximately $33.76 million. The medical instruments supplier's stock constitutes about 2.4% of Ranger's portfolio. LeMaitre Vascular recently reported Q3 EPS of $0.62, beating estimates, with revenue up 11.4% year-over-year to $61.05 million, and currently holds an average analyst rating of "Moderate Buy" with a target price of $100.20.
LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 20% Potential Upside in the Healthcare Sector
LeMaitre Vascular, Inc. (LMAT) is attracting investor attention due to its strong growth prospects in the medical instruments sector. The company, which specializes in vascular surgery devices, boasts a $1.96 billion market capitalization and impressive financials, including 11.40% revenue growth and a 15.02% return on equity. With positive analyst sentiment and an average target price suggesting a 20% upside, LeMaitre Vascular is positioned as a promising opportunity for healthcare investors.
(LMAT) Movement Within Algorithmic Entry Frameworks
The article provides an algorithmic analysis for Lemaitre Vascular Inc. (NASDAQ: LMAT), highlighting a near-term strong sentiment influencing a neutral mid and long-term outlook. Key findings include a 30.7:1 risk-reward setup targeting an 8.9% gain versus 0.3% risk, with various institutional trading strategies (Position, Momentum Breakout, Risk Hedging) outlined for different risk profiles. The analysis also details multi-timeframe signal strengths and support/resistance levels.
How (LMAT) Movements Inform Risk Allocation Models
This article analyzes Lemaitre Vascular Inc. (NASDAQ: LMAT) using AI models to inform risk allocation. It highlights a mid-channel oscillation pattern and a short setup with an exceptional 30.3:1 risk-reward ratio. The analysis presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, based on multi-timeframe signal analysis indicating strong near- and mid-term sentiment.
LeMaitre Vascular, Inc. $LMAT Shares Bought by Vest Financial LLC
Vest Financial LLC significantly increased its stake in LeMaitre Vascular (NASDAQ:LMAT) by 60%, now holding 56,279 shares valued at $4.93 million, highlighting strong institutional interest with 84.64% ownership. LeMaitre Vascular reported strong Q3 earnings, beating EPS estimates and showing an 11.4% revenue increase year-over-year, alongside setting positive FY2025 guidance. The company maintains a "Moderate Buy" analyst consensus with an average price target of $100.20, and pays a quarterly dividend.
LeMaitre Vascular (LMAT) Valuation Check After Mixed Share Performance And Growth Trends
LeMaitre Vascular (LMAT) has experienced mixed share performance and growth trends. While its P/E ratio of 36.5x is lower than some peers, it is considered expensive compared to the broader US Medical Equipment industry and an estimated fair P/E, suggesting it might be overvalued. A Discounted Cash Flow (DCF) model also indicates the current price of $85.80 is above an estimated fair value of $66.62.
LeMaitre Vascular, Inc. (LMAT) Stock Report: Analyzing 17.44% Potential Upside with Strong Revenue Growth
LeMaitre Vascular, Inc. (LMAT) is highlighted as an attractive investment in the medical instruments and supplies sector, demonstrating a potential upside of 17.44% from its current price based on analyst targets. The company showcases strong financial health with 11.40% revenue growth, a 15.02% return on equity, and a stable dividend strategy. Positive analyst ratings and bullish technical indicators further support its growth prospects for investors.
LeMaitre Vascular (LMAT) Shares Cross Above 200 DMA
LeMaitre Vascular Inc (LMAT) shares have moved above their 200-day moving average, trading at $86.95 per share, up 1.2% on the day. The company's 52-week price range is $71.42 to $105.55, with the last trade at $86.45. This movement indicates a potential positive trend for the stock.
SG Americas Securities LLC Makes New $1.10 Million Investment in LeMaitre Vascular, Inc. $LMAT
SG Americas Securities LLC recently invested $1.10 million in LeMaitre Vascular (NASDAQ:LMAT), acquiring 12,579 shares. This investment highlights broader institutional interest, with LeMaitre Vascular beating Q3 earnings expectations and setting optimistic FY2025 guidance. The company maintains a "Moderate Buy" analyst rating and has increased its quarterly dividend.
Does Analyst Optimism on Innovation and Global Expansion Reshape the Bull Case for LeMaitre Vascular (LMAT)?
LeMaitre Vascular (LMAT) is gaining analyst optimism due to its focus on innovation and international expansion in vascular surgery devices, despite its relatively small revenue base and elevated valuation. The company's specialized product portfolio and global growth ambitions are seen as catalysts, projecting $312.8 million revenue and $65.6 million earnings by 2028, leading to a fair value of $104.78. However, concerns about subscale operations, dependence on pricing power, and execution risks in international expansion remain.
Conestoga Capital Advisors LLC Cuts Stock Position in LeMaitre Vascular, Inc. $LMAT
Conestoga Capital Advisors LLC reduced its stake in LeMaitre Vascular, Inc. by 1.8% in Q3 2025, now holding 1,574,688 shares valued at $137.8 million, making it their 19th largest holding. Despite this, other hedge funds increased their positions in the medical instruments supplier. LeMaitre Vascular exceeded Q3 EPS estimates with $0.62 but slightly missed revenue projections, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $100.20.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Moderate Buy" from Analysts
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month target price of $100.20. The company recently exceeded EPS estimates but slightly missed revenue expectations, while reporting 11.4% year-over-year revenue growth and providing positive FY2025 EPS guidance. Institutional investors hold a significant portion of the stock, and the company maintains a strong financial position with a market cap of $1.90 billion and a dividend yield of approximately 1.0%.
Trading Systems Reacting to (LMAT) Volatility
This article from Stock Traders Daily discusses AI-generated trading strategies for Lemaitre Vascular Inc. (NASDAQ: LMAT), highlighting its current volatility. It outlines three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, along with multi-timeframe signal analysis and support/resistance levels. The analysis indicates neutral sentiment for mid and long-term outlooks, but strong near-term sentiment with a high risk-reward short setup.
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Shares May Have Run Too Fast Too Soon
LeMaitre Vascular, Inc. (NASDAQ:LMAT) currently has a high price-to-earnings (P/E) ratio of 34.1x, which is significantly above the market average, raising concerns despite recent strong earnings growth. While the company has shown exceptional past performance, analysts project future EPS growth of only 7.9% annually, trailing the market's 11% prediction. This disparity suggests that the current high P/E may not be sustainable, potentially putting shareholders at risk.
LeMaitre Vascular (NASDAQ:LMAT) Downgraded by Zacks Research to "Hold"
Zacks Research has downgraded LeMaitre Vascular (NASDAQ:LMAT) from a "strong-buy" to a "hold" rating, reflecting varied analyst opinions on the company. Despite beating Q3 EPS estimates with revenue growth, the stock trades near $80 with a P/E of 34.56, and analysts project average earnings of $1.94 per share for the current fiscal year. Institutional investors have actively adjusted their positions, with hedge funds and other institutions collectively owning 84.64% of the company's stock.
How Lemaitre Vascular Inc. (LMAT) Affects Rotational Strategy Timing
This article analyzes Lemaitre Vascular Inc. (LMAT) and its impact on rotational strategy timing, highlighting weak near-term sentiment and a mid-channel oscillation pattern. It presents an exceptional risk-reward setup, targeting a 10.2% gain with minimal risk, and details three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis and support/resistance levels for LMAT.
Harbor Capital Advisors Inc. Trims Stake in LeMaitre Vascular, Inc. $LMAT
Harbor Capital Advisors Inc. significantly reduced its stake in LeMaitre Vascular, Inc. in Q3 2025, selling 15,770 shares and retaining 6,512 shares valued at $570,000. LeMaitre Vascular reported Q3 EPS of $0.62, surpassing estimates, with revenue slightly below expectations but showing an 11.4% year-over-year increase. The company's stock currently trades around $83.78 with a "Moderate Buy" consensus rating and an average price target of $100.20.
Rice Hall James & Associates LLC Sells 35,684 Shares of LeMaitre Vascular, Inc. $LMAT
Rice Hall James & Associates LLC reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 16.7%, selling 35,684 shares and now owning 178,186 shares valued at $15.59 million. LeMaitre Vascular reported strong Q3 earnings of $0.62 per share, beating consensus, with revenue up 11.4% year-over-year, and maintains a "Moderate Buy" consensus analyst rating.
Reflecting On Surgical Equipment & Consumables - Specialty Stocks' Q3 Earnings: LeMaitre (NASDAQ:LMAT)
This article reviews the Q3 2025 earnings for surgical equipment and consumables - specialty stocks, highlighting individual company performances. While the sector generally met revenue expectations, LeMaitre (LMAT) had a mixed quarter with revenue shortfalls, and Intuitive Surgical (ISRG) significantly outperformed. The article also provides a brief market update discussing the economic impact of Fed rate cuts and the recent presidential election.
Congress Asset Management Co. Has $60.58 Million Stake in LeMaitre Vascular, Inc. $LMAT
Congress Asset Management Co. increased its stake in LeMaitre Vascular, Inc. ($LMAT) by 2.7% in Q3, now holding 692,266 shares valued at $60.58 million. The company reported strong Q3 earnings, beating EPS estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $100.20. LeMaitre Vascular also declared a quarterly dividend of $0.20 per share, representing an annualized yield of 0.9%.
LeMaitre Vascular (NASDAQ:LMAT) Hasn't Managed To Accelerate Its Returns
LeMaitre Vascular (NASDAQ:LMAT) has not shown an acceleration in its Return on Capital Employed (ROCE), which currently stands at 11%, aligning with industry averages. Despite a 160% increase in capital employed over the last five years, the ROCE has remained consistently stable at 11%, indicating the company is a compounding machine but not accelerating its returns. The stock has provided a 132% return to shareholders over the past five years, suggesting investors recognize promising trends even without an accelerated ROCE.
American Century Companies Inc. Has $2.82 Million Holdings in LeMaitre Vascular, Inc. $LMAT
American Century Companies Inc. has significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 233.0% in the second quarter, now holding 34,008 shares valued at $2.82 million. Several other institutional investors also adjusted their positions in LMAT, which has a current market capitalization of $1.88 billion and recently announced a quarterly dividend of $0.20 per share. The medical instruments supplier reported strong Q3 earnings, topping consensus estimates, and has received a "Moderate Buy" consensus rating from analysts.
First Trust Advisors LP Increases Stock Position in LeMaitre Vascular, Inc. $LMAT
First Trust Advisors LP significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 52.7% during Q2, now owning 612,028 shares valued at over $50 million. Other institutional investors also adjusted their holdings, contributing to 84.64% of the stock being institutionally owned. The company recently announced a quarterly dividend of $0.20 per share, and analysts have a "Moderate Buy" consensus rating with an average target price of $100.20.
LeMaitre Vascular, Inc. $LMAT Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 13.7% in Q2, selling 23,748 shares. The medical instruments supplier reported Q3 EPS of $0.62, beating consensus, on revenue of $61.05 million, and expects FY2025 EPS between $2.48 and $2.53. The company pays a quarterly dividend of $0.20 and has an average analyst rating of "Moderate Buy" with a $100.20 target price.
LeMaitre Vascular (NASDAQ:LMAT) Cut to Hold at Wall Street Zen
LeMaitre Vascular (NASDAQ:LMAT) was downgraded by Wall Street Zen from a "buy" to a "hold" rating, though the analyst consensus remains a "Moderate Buy" with an average target price of $100.20. The company recently exceeded EPS estimates but slightly missed revenue projections, and has provided FY2025 and Q4 guidance. Institutional investors have also been adjusting their positions in the stock.
Quantbot Technologies LP Increases Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Quantbot Technologies LP significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 934.5% in Q2, acquiring 32,979 shares valued at $2.74 million. Other institutional investors have also adjusted their holdings. The company reported strong Q2 earnings, beating EPS expectations, and analysts currently rate the stock as a "Moderate Buy" with a $100.20 target price.
Inceptionr LLC Buys New Position in LeMaitre Vascular, Inc. $LMAT
Inceptionr LLC has acquired a new stake of 3,061 shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the second quarter, valuing their new position at approximately $254,000. Institutional investors now collectively own 84.64% of the company. LeMaitre Vascular reported Q2 EPS of $0.62, surpassing the consensus estimate of $0.57, though revenue slightly missed expectations at $61.05 million.
Russell Investments Group Ltd. Cuts Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Russell Investments Group Ltd. reduced its stake in LeMaitre Vascular, Inc. by 2.6% in the second quarter, selling 6,877 shares, though it still owns 257,384 shares worth $21.38 million. Despite this, several other institutional investors increased their positions, maintaining an institutional ownership of about 84.64%. The company reported strong Q2 earnings, exceeding EPS estimates, and has provided positive FY2025 EPS guidance, alongside a consistent quarterly dividend.
LeMaitre to Participate in Upcoming Investor Conferences
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its management will participate in three upcoming investor conferences. These include the Jefferies London Healthcare Conference on November 18, 2025, the Wolfe Research 7th Annual Healthcare Conference on November 19, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. Dorian LeBlanc, CFO, and David Roberts, President, are scheduled to present at these events.
LeMaitre to Participate in Upcoming Investor Conferences
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in three upcoming investor conferences in November and December 2025. CFO Dorian LeBlanc will present at the Jefferies London Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference, while President David Roberts will present at the Wolfe Research 7th Annual Healthcare Conference. The company, a provider of devices for peripheral vascular disease, aims to engage with investors regarding its business.
LeMaitre (Nasdaq: LMAT) to join Jefferies, Wolfe and Piper Sandler investor conferences
LeMaitre Vascular (Nasdaq: LMAT) announced its management will participate in three investor conferences in November and December 2025. CFO Dorian LeBlanc and President David Roberts will represent the company at the Jefferies London Healthcare Conference, Wolfe Research 7th Annual Healthcare Conference, and Piper Sandler 37th Annual Healthcare Conference. The company's stock, LMAT, experienced a mild negative reaction, declining 0.37% on the day this news was published.
Earnings call transcript: LeMaitre Vascular Q3 2025 EPS beats, stock dips
LeMaitre Vascular Inc. reported Q3 2025 adjusted earnings per share of $0.62, beating forecasts, but revenue of $61 million missed expectations. Despite the EPS beat, the stock dipped 0.56% in after-hours trading. The company provided full-year revenue guidance of $248 million, representing 13% growth, and projects adjusted EPS of $2.37, a 22% increase from 2024.
LeMaitre Vascular Inc. Q3 Profit Increases, Beats Estimates
LeMaitre Vascular Inc. (LMAT) reported a significant increase in its third-quarter profit, reaching $17.36 million, or $0.75 per share, compared to $11.14 million, or $0.49 per share, in the previous year. The company's adjusted earnings of $0.62 per share surpassed analysts' expectations of $0.56 per share. Revenue for the period also saw an 11.4% rise, totaling $61.05 million.
Avoiding Lag: Real-Time Signals in (LMAT) Movement
This article analyzes Lemaitre Vascular Inc. (LMAT) using AI models, indicating a neutral sentiment across all time horizons and suggesting a wait-and-see approach. It details three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 40.1:1 risk-reward setup targeting an 11.4% gain versus a 0.3% risk.
LeMaitre Vascular (LMAT) Analyst Ratings Unchanged by Barrington Research | LMAT Stock News - GuruFocus
Barrington Research maintained its "Outperform" rating and $95.00 price target for LeMaitre Vascular (LMAT) following an analyst update on October 15, 2025. This decision mirrors prior ratings and reflects sustained analyst confidence in the medical device company. Wall Street analysts forecast an average price target of $104.63 for LMAT, suggesting a 19.74% upside from its current price, and a consensus "Outperform" recommendation.
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
LeMaitre Vascular, Inc. announced that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close. The company will also hold a conference call the same day at 5:00 PM EST to discuss the results, business highlights, and company outlook. Investors can register online to access the live call, or access the audio webcast and replay at ir.lemaitre.com.
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
LeMaitre Vascular, Inc. announced it will release its third-quarter 2025 financial results on Thursday, November 6, 2025, after the market close. A conference call is scheduled for 5:00 PM EST on the same day to discuss the results and company outlook. The company is a global provider of devices, implants, and services for peripheral vascular disease.
Two Mass. medical device companies issued FDA warning letters
The FDA has issued warning letters to two Massachusetts-based medical device companies located in Westborough and Burlington. The letters concern their medical devices, indicating potential compliance issues identified by the U.S. Food and Drug Administration. This action highlights ongoing regulatory scrutiny in the medical device sector.
FDA issues warnings to two Mass. medical device firms
The U.S. Food and Drug Administration has issued warning letters to two Massachusetts medical device companies. One firm, Burlington-based LeMaitre Vascular Inc., received a warning for quality system regulation violations during the manufacturing of its Artegraft Collagen Vascular Grafts. The inspection took place at its North Brunswick, New Jersey site.
LeMaitre Q2 2025 Financial Results
LeMaitre Vascular, Inc. reported strong Q2 2025 financial results, with sales of $64.2 million, up 15%, and diluted EPS of $0.60, also up 16%. The company increased its full-year 2025 guidance for both sales and profit, citing strong performance in catheters and grafts and the OUS launch of Artegraft. LeMaitre also announced a quarterly dividend of $0.20 per share and discussed its share repurchase program.
LeMaitre Vascular Inc (LMAT) Q2 2025: Everything You Need To Know Ahead Of Earnings
LeMaitre Vascular Inc (NASDAQ:LMAT) is scheduled to release its Q2 2025 earnings on August 5, 2025, with revenue expected at $62.48 million and earnings at $0.57 per share. Analyst estimates for full-year 2025 revenue have increased, while earnings estimates have slightly declined. The average target price from analysts suggests a potential upside of 28.65% from its current price, with a consensus "Outperform" recommendation.
